Quick Search:

uzh logo
Browse by:

Zurich Open Repository and Archive

Maintenance: Tuesday, 5.7.2016, 07:00-08:00

Maintenance work on ZORA and JDB on Tuesday, 5th July, 07h00-08h00. During this time there will be a brief unavailability for about 1 hour. Please be patient.

Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-41548

Studer, G; Brown, M; Salgueiro, E B; Schmückle, H; Romancuk, N; Winkler, G; Lee, S J; Sträuli, A; Kissling, B; Dummer, R; Glanzmann, C (2011). Grade 3/4 dermatitis in head and neck cancer patients treated with concurrent Cetuximab and IMRT. International Journal of Radiation Oncology, Biology and Physics, 81(1):110-117.

[img]Published Version
PDF - Registered users only
View at publisher


PURPOSE: To assess the rate of serious (>Grade 2, CTCAE 3.0) dermatitis in our head-and-neck cancer (HNC) patients undergoing simultaneous integrated boost intensity-modulated radiotherapy with concomitant cetuximab (SIB-IMRT-cetuximab). We hypothesized a positive association between the radiation dose to the skin and the degree of dermatitis in patients receiving cetuximab. METHODS AND MATERIALS: Between April 2006 and December 2009, 99 HNC patients underwent SIB-IMRT-cetuximab. In 69/99 (70%), systemic treatment consisted of concomitant cetuximab only, whereas 30 (30%) were switched from concomitant cisplatin to concomitant cetuximab. Treatment-related dermatitis was prospectively monitored. Ninety-nine patients treated with four to seven concomitant cycles of cisplatin only served as an internal control group. The radiation dose delivered to the skin was measured and related to dermal reactions. RESULTS: Grade 3/4 dermatitis developed in 34% of the cetuximab cohort, which was substantially higher than in the control cohort (3%, p < 0.01). No cases of skin necrosis or other fatal events related to cetuximab have occurred so far. A significantly larger mean skin area was found exposed to high radiation doses in patients with severe cetuximab-related dermatitis, compared with those without (p < 0.01). CONCLUSION: Concomitant cetuximab resulted in a approximately 10-fold increase in the rate of severe transient dermatitis compared with the use of concomitant cisplatin. We found a positive association between the incidence of Grade 3/4 dermatitis and the radiation dose delivered to the skin in patients receiving cetuximab.


15 citations in Web of Science®
21 citations in Scopus®
Google Scholar™



3 downloads since deposited on 07 Jan 2011
0 downloads since 12 months

Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Radiation Oncology
04 Faculty of Medicine > University Hospital Zurich > Dermatology Clinic
Dewey Decimal Classification:610 Medicine & health
Deposited On:07 Jan 2011 14:28
Last Modified:05 Apr 2016 14:32
Publisher DOI:10.1016/j.ijrobp.2010.05.018
PubMed ID:20732757

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page